Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Altimmune (ALT) Preferred Shares Issued (2016 - 2017)

Altimmune (ALT) reported Preferred Shares Issued of $13.0 million for Q3 2017, up 548.63% year-over-year from $2.0 million in Q3 2016, and up 548.63% on a QoQ basis from $2.0 million in Q3 2016.

Altimmune (ALT) has 2 years of Preferred Shares Issued data on file, last reported at $13.0 million in Q3 2017.

  • Quarterly Preferred Shares Issued rose 548.63% year-over-year to $13.0 million in Q3 2017, while the trailing twelve-month figure through Dec 2017 was $15.0 million (changed N/A YoY) and the FY2017 annual result came in at $13.0 million, up 129.46% from the prior year.
  • Preferred Shares Issued advanced to $13.0 million in Q3 2017 per ALT's latest filing, from $2.0 million in the prior quarter.
  • Across five years, Preferred Shares Issued topped out at $13.0 million in Q3 2017 and bottomed at $2.0 million in Q3 2016.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Shares Issued (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Altimmune 379.61 Mn 379.61 Mn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2017 12.97 Mn
Sep 30, 2017 12.97 Mn
Sep 30, 2016 2.00 Mn
Sep 30, 2016 2.00 Mn